The acquisition is expected to expand Catalent’s development & clinical services business and enhance its position in development solutions and advanced delivery technologies for drugs, biologics, and consumer health products.
Catalent’s development & clinical services business offers clinical supply solutions, analytical services for both small and large molecule drugs, inhaled and sterile product development, and regulatory consulting.